adj ep beat consensu due oper perform pharma
medic delay invest relat cost optim guidanc
rais modestli impli less back-half ep growth delay invest kick
make earn ramp less steep encourag improv underli
fundament medic pharma
compani report streetaccount thomson eikon cowen compani
report rev y/i expect adj
oper incom y/i expect report
adj ep y/i ahead consensu driven
primarili better expect perform medic
segment along contribut lower anticip share count
despit tax rate come bp wors expect management note
better expect result due specialti growth brand volum revers
ny opioid stewardship act time corpor expens
pharma revenu came y/i beat expect
oper profit y/i compar consensu
revenu driven growth pharmaceut specialti distribut custom
partial off-set divestitur china busi
medic revenu y/i slightli miss consensu
oper profit y/i beat consensu
pleas see page report import disclosur
would remain sidelin management continu execut turnaround
strategi cordi despit solid perform pharma segment turnaround
medic said progress in-lin expect servic level fill rate
cordi back order inventori expens trend management
remain confid cordi path profit growth end
better expect result pharma particularli top-lin beat larg due
specialti indic us macro environ may improv
progress turnaround medic
integr patient recoveri
updat management strateg initi
growth
gross margin pressur
ebit margin
share repo
top-lin growth high-singl digit
due better expect growth
specialti medic
gross margin closer greater
expect benefit red oak
sg come better oper
leverag cost reduct
share repo greater
top-lin growth low-singl
digit due weaker expect
gross margin due weaker
expect gener profit
 restructur cost weigh
share repo
one three largest pharmaceut distribut compani
 oper billion pharmaceut market compani distribut
comprehens offer brand-nam gener pharmaceut over-the-count
healthcar product home healthcar suppli equip wide varieti
healthcar provid locat throughout includ acut care hospit health
system independ chain retail pharmaci mail-ord facil physician clinic
alternate-sit facil cardin oper today two report segment
pharmaceut medic cardin recent focus home health space
management rais adj ep guidanc well revenu
guidanc mid-singl digit percentag growth low-singl digit percentag growth
addit slightli lower tax rate guidanc
share count guidanc interest guidanc
capit expenditur guidanc re-affirmed
pharma management rais revenu guidanc mid-singl digit percentag growth low-
singl digit percentag growth re-affirmed oper profit guidanc high-singl
medic management lower revenu guidanc approxim flat low-singl digit
percentag growth re-affirmed oper profit guidanc mid- high-singl digit
although revis guidanc impli lower expect back-half see
posit develop flatten back-half ramp achiev full-year guidanc
believ rel steep
interestingli despit consider beat quarter well slightli improv
tax share count outlook guidanc rais midpoint
high-end believ larg function time due delay
invest relat cost optim substanti impact
result base convers management appear track in-line
remain sidelin increment posit management appear
make progress strateg initi medic posit posit long-
term growth evidenc segment result fact management note servic level
fill rate cordi back order inventori expens trend
management also reiter confid cordi path profit growth
end anoth posit take-away better expect result pharma
particularli top-lin beat larg due specialti indic us macro
environ may improv
rais adj ep estim maintain adj ep
estim slightli rais price target base revis
dcf analysi indic share trade adj ep estim
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep chang year-over-year oper incom continu continu year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
compani report cowen compani
asset trade receiv merchandis prepaid expens asset held sale discontinu ops- current pp goodwil total current liabil current portion long-term account accru liabil busi held sale disc ops- current long-term defer tax redeem non-controlling stockhold equiti common retain common share cumul foreign currenc non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
compani report cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci gain sale provis loss account charg reorg busi gain sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani report cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci gain sale asset loss debt extinguishment- gain sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal securities- proce divestitur dispos held sale assets- proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting consideration- net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- reclassfii asset held sale- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ
abil turn around medic segment integr risk relat cordi patient
recoveri manag abil deploy capit effect faster-than-
expect turnaround cordi
